🟢 First Tracks Biotherapeutics is trading 21% up in pre-market ahead of October 12 ANB033 trial data

First Tracks Biotherapeutics is trading at $38.50, up 20.88%, ahead of its scheduled October 12 release of top-line ANB033 trial data.

• The update is top-line Cohort 1 data from the Phase 1b ANB033 celiac-disease trial, scheduled for a morning release.
• An investor webcast is scheduled for 8:30 a.m. ET. Results had not been presented as of 4:09 a.m. ET.
• Major indexes were modestly higher, not showing a broad rally of similar scale.